Artelo Biosciences, Inc.
  • About
    • About Artelo
    • Management
    • Board of Directors
    • Scientific Advisors
    • Contact
  • Pipeline
    • Overview
    • ART27.13
    • ART26.12
    • ART12.11
  • Science
    • Overview
    • Publications
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Media
  • Menu Menu
  • Twitter
  • LinkedIn
  • Facebook

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Media
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Email Alerts
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Media
Oct 01, 2025 4:05pm EDT

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025 8:30am EDT

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025 7:15pm EDT

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025 8:30am EDT

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 10, 2025 8:30am EDT

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

Sep 05, 2025 4:05pm EDT

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 04, 2025 8:37am EDT

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 03, 2025 4:35pm EDT

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 03, 2025 11:33am EDT

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 03, 2025 8:45am EDT

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 - Artelo Biosciences, Inc.     info@artelobio.com    |     Terms of Use    |     Privacy Policy
  • Twitter
  • LinkedIn
  • Facebook